Showing 1981-1990 of 2314 results for "".
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study
- Study Finds Pfizer, AstraZeneca’s COVID-19 Vaccines “Highly Effective” Against Indian Varianthttps://modernod.com/news/study-finds-pfizer-astrazenecas-covid-19-vaccines-highly-effective-against-indian-variant/2479237/An analysis by Public Health England (PHE) suggests that two doses of COVID-19 vaccines from Pfizer/BioNTech and AstraZeneca are “highly effective” against the B.1.617.2 coronavirus variant first identified in India, the UK government announced on Saturday, according to a FirstWord re
- Essilor Receives FDA Breakthrough Device Designation for Essilor Stellest Spectacle Lenshttps://modernod.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/Essilor announced that the FDA has granted Breakthrough Device designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as
- FDA Authorizes Pfizer, BioNTech’s COVID-19 Vaccine for Younger Adolescentshttps://modernod.com/news/fda-authorizes-pfizer-biontechs-covid-19-vaccine-for-younger-adolescents/2479191/The FDA on Monday expanded the emergency-use authorization (EUA) for Pfizer and BioNTech’s vaccine BNT162b2 to include preventing COVID-19 in adolescents 12 through 15 years of age, according to a FirstWord report. The two-dose mRNA-based vaccine was initially granted an EUA in December for
- Sinopharm’s COVID-19 Vaccine Granted WHO Emergency Listinghttps://modernod.com/news/sinopharms-covid-19-vaccine-granted-who-emergency-listing/2479184/The World Health Organization (WHO) on Friday approved Sinopharm’s COVID-19 vaccine for emergency use, paving the way for millions more doses to be included into the COVAX program in the coming weeks or months for rollout in developing countries, according to a FirstWord report. The decisio
- Melling Medical to Distribute Optos Technology to Federal Health Facilitieshttps://modernod.com/news/melling-medical-to-distribute-optos-technology-to-federal-health-facilities/2479175/MellingMedical today announced a new distribution agreement with Optos Inc. to deliver their state-of-the-art equipment to facilities across the federal health care system. “As they work to accommodate growing caseloads, doctors in the federal health system are looking for t
- CooperVision Expands Prescription Options for Biofinity XR Toric Contact Lenseshttps://modernod.com/news/coopervision-expands-prescription-options-for-biofinity-xr-toric-contact-lenses/2479170/CooperVision is introducing a broader range of expanded parameters for its Biofinity XR toric lenses. The addition of sphere powers from ±10.50D to ±20.00D nearly doubles the number of available prescription options specific to this lens, making it easier for eye care professionals to fit patient
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Okogen Announces Interim Analysis Results From RUBY Phase 2 Trial for Acute Adenoviral Conjunctivitis Drug Candidatehttps://modernod.com/news/okogen-announces-interim-analysis-results-from-ruby-phase-2-trial-for-acute-adenoviral-conjunctivitis-drug-candidate/2479140/Okogen announced the interim analysis results from RUBY, the company’s phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301
- Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Trial of AR-15512 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-for-the-treatment-of-patients-with-dry-eye-disease/2479134/Aerie Pharmaceuticals announced the completion of patient enrollment for COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 Agonist) ophthalmic solution for the treatment of patients with dry eye disease. The first patient to enter this randomized, double-masked, vehicle-controlled phas